279 related articles for article (PubMed ID: 21973261)
21. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(50):1705-8. PubMed ID: 22189893
[TBL] [Abstract][Full Text] [Related]
22. [Safety of the bivalent human papillomavirus vaccine--results following administration of more than 192,000 doses].
van der Maas NA; Kemmeren JM; de Melker HE
Ned Tijdschr Geneeskd; 2009; 153():A964. PubMed ID: 19930738
[TBL] [Abstract][Full Text] [Related]
23. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.
Gee J; Naleway A; Shui I; Baggs J; Yin R; Li R; Kulldorff M; Lewis E; Fireman B; Daley MF; Klein NP; Weintraub ES
Vaccine; 2011 Oct; 29(46):8279-84. PubMed ID: 21907257
[TBL] [Abstract][Full Text] [Related]
24. Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia.
Brotherton JM; Mullins RM
Cancer Epidemiol; 2012 Jun; 36(3):298-302. PubMed ID: 22204834
[TBL] [Abstract][Full Text] [Related]
25. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies.
Klein NP; Ray P; Carpenter D; Hansen J; Lewis E; Fireman B; Black S; Galindo C; Schmidt J; Baxter R
Vaccine; 2010 Jan; 28(4):1062-8. PubMed ID: 19896453
[TBL] [Abstract][Full Text] [Related]
26. The case for HPV immunization.
Campos-Outcalt D
J Fam Pract; 2009 Dec; 58(12):660-4. PubMed ID: 19961821
[TBL] [Abstract][Full Text] [Related]
27. Factors predicting completion of the human papillomavirus vaccine series.
Gold R; Naleway A; Riedlinger K
J Adolesc Health; 2013 Apr; 52(4):427-32. PubMed ID: 23298984
[TBL] [Abstract][Full Text] [Related]
28. Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study.
Liu EY; Smith LM; Ellis AK; Whitaker H; Law B; Kwong JC; Farrington P; Lévesque LE
CMAJ; 2018 May; 190(21):E648-E655. PubMed ID: 29807937
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance.
Gold MS; McIntyre P
Sex Health; 2010 Sep; 7(3):320-4. PubMed ID: 20719221
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females.
Yih WK; Greene SK; Zichittella L; Kulldorff M; Baker MA; de Jong JL; Gil-Prieto R; Griffin MR; Jin R; Lin ND; McMahill-Walraven CN; Reidy M; Selvam N; Selvan MS; Nguyen MD
Vaccine; 2016 Jan; 34(1):172-8. PubMed ID: 26549364
[TBL] [Abstract][Full Text] [Related]
32. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study.
Arnheim-Dahlström L; Pasternak B; Svanström H; Sparén P; Hviid A
BMJ; 2013 Oct; 347():f5906. PubMed ID: 24108159
[TBL] [Abstract][Full Text] [Related]
33. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom.
Willame C; Rosillon D; Zima J; Angelo MG; Stuurman AL; Vroling H; Boggon R; Bunge EM; Pladevall-Vila M; Baril L
Hum Vaccin Immunother; 2016 Nov; 12(11):2862-2871. PubMed ID: 27428517
[TBL] [Abstract][Full Text] [Related]
34. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
[TBL] [Abstract][Full Text] [Related]
35. Evaluating associations between sources of information, knowledge of the human papillomavirus, and human papillomavirus vaccine uptake for adult women in California.
Almeida CM; Tiro JA; Rodriguez MA; Diamant AL
Vaccine; 2012 Apr; 30(19):3003-8. PubMed ID: 22326776
[TBL] [Abstract][Full Text] [Related]
36. On the relationship between human papilloma virus vaccine and autoimmune diseases.
Pellegrino P; Carnovale C; Pozzi M; Antoniazzi S; Perrone V; Salvati D; Gentili M; Brusadelli T; Clementi E; Radice S
Autoimmun Rev; 2014 Jul; 13(7):736-41. PubMed ID: 24468416
[TBL] [Abstract][Full Text] [Related]
37. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011.
Schmidt MA; Gold R; Kurosky SK; Daley MF; Irving SA; Gee J; Naleway AL
J Adolesc Health; 2013 Nov; 53(5):637-41. PubMed ID: 24138765
[TBL] [Abstract][Full Text] [Related]
38. The incidence of genital warts in Australian women prior to the national vaccination program.
Brotherton JM; Heywood A; Heley S
Sex Health; 2009 Sep; 6(3):178-84. PubMed ID: 19653953
[TBL] [Abstract][Full Text] [Related]
39. Does HPV vaccination affect women's attitudes to cervical cancer screening and safe sexual behaviour?
Mather T; McCaffery K; Juraskova I
Vaccine; 2012 May; 30(21):3196-201. PubMed ID: 22425789
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil.
Haupt RM; Sings HL
J Adolesc Health; 2011 Nov; 49(5):467-75. PubMed ID: 22018560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
